Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Part of paid clinical trials in St. Petersburg, Florida.
- Sponsor
- Merus B.V.
- Study ID
- NCT07353957
- Phase
- PHASE2
- Status
- Withdrawn
Conditions
- Lung Cancer - Non Small Cell Non-Squamous
- Lung Cancer - Non Small Cell Squamous
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Petosemtamab + Pembrolizumab — COMBINATION_PRODUCTPetosemtamab + Pembrolizumab
Study Details
The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
Key Dates
- First listed
- Jan 21, 2026
- Start date
- Mar 27, 2025
- Status verified
- Jun 2026
- Primary completion
- May 31, 2028
- Completion
- Feb 27, 2031
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: First line squamous non-small cell lung cancer patients
- Experimental: First line non-squamous non-small cell lung cancer patients
Primary Outcome Measure
Objective response rate per investigator assessment [ Time Frame: Up to 4.5 years ]
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Florida Cancer Specialists - North | St. Petersburg | Florida | 33701-4553 | - |
| Memorial Sloan Kettering Cancer Center | Long Island City | New York | 11101 | - |
| Tennessee Site 2 | Chattanooga | Tennessee | 37403 | - |
| Tennessee Site 1 | Nashville | Tennessee | 37209 | - |
| Virginia Site 2 | Blacksburg | Virginia | 24060 | - |
| Virginia Site 1 | Fairfax | Virginia | 22031 | - |